

5 June 2024

## Respiri raises \$1 million through Additional Placement

**Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory healthcare management and remote patient monitoring (RPM), is pleased to announce that it has received firm commitments to raise a further \$A1 million (before costs) (the "**Placement**") from sophisticated and professional investors.

This unsolicited offer was made on the back of recent USA business progress by the Company and further underpins investor confidence in Respiri's strategy, execution capability and leadership.

Under the terms of the Placement, the Company will issue 33,333,333 new fully paid ordinary shares ("**New Shares**") at an issue price of \$0.03 per New Share. This issue price represents a 3.45% premium to the Company's last closing price of \$0.029 on Tuesday 4 June 2024. The Placement is in addition to the A\$6.5 million placement announced by the Company on 14 December 2023 and the \$A1.6 million placement announced by the Company on 30 April 2024 ("**Prior Placements**"), taking the total funding raised to A\$9.1M. Both of the Prior Placements were also conducted at an issue price of \$0.03.

The Placement will utilize the Company's existing Listing Rule 7.1A capacity. The Company expects to complete allotment of the New Shares under the Placement by 7 June 2024.

Funds raised from the placement will be applied to recently announced contracted clients' patient profiling, segmentation, targeting and onboarding, the acceleration of the Company's "Clinic in Cloud" ("CiC") programs - that will rapidly expand the Company's RPM and expanded service business in the US - and for general working capital purposes which is forecast to provide sufficient funding to allow the Company to reach a monthly breakeven performance in late CY 2024.

Respiri is pleased with both the strong market support and strategic opportunities its broadening stakeholder base and core RPM offering rollout is generating in a high-growth, rapidly transforming market.

-ENDS-

**For further information, investors and media please contact:**

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

### About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management and Remote Patient Monitoring services. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia and in New York, USA.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)

### About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.